TEN YEARS AGO KGI ACTED on a bold idea: create a graduate institution dedicated to education and research that would translate the power and potential of the life sciences into practice for the benefit of society. The task was daunting. Starting any new school of higher education poses many challenges, but KGI’s formation was even more ambitious.

KGI aimed to formulate an academic program aimed at establishing 10 endowed scholarship funds and an appreciation for the business of bioscience: finance, management, marketing, regulatory affairs, licensing and patents—issues and items at the heart of the rapidly evolving and highly competitive industry.

KGI’s faculty of skilled educators combines an understanding of the biological sciences, engineering, and computational analysis with an appreciation for the business of bioscience: finance, management, marketing, regulatory affairs, licensing and patents—issues and items at the heart of the rapidly evolving and highly competitive industry.

KGI has achieved remarkable success in a relatively short time. This year, KGI celebrates the achievements of the past decade. Our 10th Anniversary event (see p. 4–5) recognized the hard work and wise judgment employed by those who are responsible for KGI’s success. We chose to honor three of our founders; without them, this institution simply would not exist.

Henry “Hank” Riggs is KGI’s founding president. He conceived KGI and dedicated himself to its creation. Robert Day is chairman and president of the W.M. Keck Foundation. He and the Keck Foundation led the way through a spectacular act of “venture philanthropy,” issuing an initial grant of $50 million to start KGI, followed by a second challenge grant of $20 million in 2005. Sidney “Jim” Weinberg, Jr., is KGI’s first board chair. His financial and intellectual generosity helped launch KGI, including the Weinberg Challenge aimed at establishing 10 endowed scholarship programs. KGI bestowed its first honorary degrees to these remarkable individuals at our 2007 commencement ceremony.

There are countless others we have to thank for their dedication and contributions to KGI. Marsh Cooper, for instance, a longtime trustee and one of KGI’s closest friends, will be honored in October 2007 with the dedication of the bioengineering laboratory in his name (see story, next page).

In this celebratory year of our 10th Anniversary, we honor not only Marsh and our founders but all who have supported KGI. To you who have helped make this institution the success that it is, I express my deepest appreciation. I invite you to become involved in our next decade of innovation, so that we can continue to lead, bringing the benefits of the life sciences to all, through education, research and service.

WHERE MOST SAW ONLY earth and rocks, Marsh Cooper saw opportunity. A trained geologist, Cooper has spent a lifetime in the mining and oil industry searching for economic concentrations of minerals and metals. His ability to see potential where others could not allowed him to embark on new frontiers—whether it was finding minerals and ores or embracing the concept of Keck Graduate Institute (KGI) during its infancy.

A steadfast supporter of higher education, Cooper has helped guide the development of KGI since the late 1990s as a member of KGI’s Board of Trustees. For his longstanding dedication, KGI has chosen to honor Cooper by establishing the Marsh A. Cooper Laboratory of Bioengineering.

“Marsh is an engineer and a geologist,” said KGI President Sheldon Schuster, PhD. “He is also a strong believer in the biosciences and in the American higher education system, so it seemed only fitting to pay tribute to a man who has done so much for our institution.”

The idea of honoring Cooper was first broached by Robert Day, chairman and president of the W.M. Keck Foundation, which helped found KGI with an initial grant of $50 million in 1997 and provided a second matching grant of $20 million in 2005. Day and Cooper go back a long way, to when Day’s uncle, Howard B. Keck, son of William Myron Keck, helped create one of the world’s leading oil companies, Standard Oil of California. Henry “Hank” Riggs, KGI’s founding president, approached Day about his idea to establish a graduate school dedicated to the applied life sciences. Cooper said he was happy to get involved in the development of KGI, adding, “It has been a great pleasure to watch this school grow from an idea of Hank’s to a real success story.”

Day has pledged to give KGI $1 million to name the Cooper Laboratory which was matched by an anonymous donor who also pledged $1 million. Others who have contributed are President Schuster; Robert E. Curry, KGI’s chairman of the board; John E. Kolb, manager of Rincon Ranch; James Paul Lower, partner at Hanna and Morton LLP and general counsel for the Keck Foundation; Stephen J. Ryan, president of the Doheny Eye Institute at USC; Simon Ramo, co-founder of TRW; and Sidney “Jim” Weinberg, Jr., KGI co-founder and board chairman emeritus, through the Sidney J. Weinberg Foundation.

The bioengineering laboratory at KGI currently consists of over 2,900 sq. ft. with state-of-the-art photolithographic microfabrication equipment. With the establishment of the Cooper lab, KGI will be able to expand upon the vital work being conducted in the bioengineering facilities that help support the institution’s graduate programs and sponsored-research performed by faculty.
"In 1997, KGI was an idea. Today, it is an institution," declared KGI President Sheldon Schuster, PhD, at a special celebration marking Keck Graduate Institute’s 10th Anniversary. "We began as a hypothesis: In order to realize the promise of the life sciences, doesn’t the industry need special kinds of people with skills in science and business? Doesn’t it need professionals who understand how to harness basic research and translate its discoveries into products and applications that can be used by real people to improve lives and to benefit humanity?"

In just 10 years KGI has established itself as the premiere graduate institution for educating tomorrow’s leaders of the biosciences. KGI’s Master of Bioscience program—emphasizing integrated and applied curriculum, teamwork and real-world projects—is producing graduates that are employed at a rate of 97% within six months of graduation. KGI is also conducting laboratory research that is aiding in the fights against infectious disease, heart failure, breast cancer, bioterror and more.

With these many accomplishments in mind, KGI celebrated its 10th Anniversary in May with special events honoring everyone who has helped make KGI a remarkable success—from students and alumni to faculty and staff, plus KGI’s founders. The occasion provided the perfect opportunity for KGI to recognize and honor three individuals who were pivotal to KGI’s creation: Henry “Hank” Riggs, KGI’s founding president; Robert Day, chairman and president of the W.M. Keck Foundation; and Sidney “Jim” Weinberg, Jr., KGI’s founding board chair.

In keeping with the spirit of remembrance, KGI asked Busenberg (KGI’s first employee) to assemble a collection of historical materials for the school’s first time capsule. The materials were on display in KGI’s Founders Room where attendees of the alumni reception joined with faculty, staff and other guests for a special pre-dinner reception.

A Day to Remember

ON MAY 12, the festivities began with a special alumni reunion that brought together members of KGI’s first five graduating classes on KGI’s alumni patio. Alumni reunited not only with former classmates but also with former KGI staff in attendance, including Riggs, John Friesman (admissions), Elaine Turner (career services), Mary Jensen (foundation relations) and Bonnie Busenberg (vice president of administration).

"Many of us were thrilled that Elaine Turner, our former director of career services, paid a visit," said Johanna Mullen, Class of 2004. "It was fun to chat with her and share where we are all now working, as she helped many of us in our internship and career searches. It was also a delight to catch up with [KGI Board Chairman] Bob Curry and his wife, Winifred. Many of us were fortunate enough to take Bob’s entrepreneurship class."

Tom Storey (MBS ‘03) enjoyed the “opportunity to chat with my student colleagues and to hear their experiences in applying the KGI education to industry. I walked away from the evening feeling that KGI and its students have accomplished a great deal and have much to be proud of.”
DEAR FRIENDS, When I first learned about KGI in the 1990s, it was little more than a concept of Henry “Hank” Riggs, who was then president of Harvey Mudd College. Hank sent me a four-page document outlining his idea for a bold new graduate school devoted to educating the future leaders of the biosciences. As a healthcare venture capitalist, I found myself staring at the most exciting proposal for a start-up I had ever seen. I was hooked.

Today, KGI is now a reality, having evolved from ambitious idea to innovative institution now celebrating its 10th Anniversary. But my excitement hasn’t waned—in fact, it is as strong as ever. Why? Because of what lies ahead. KGI has only begun to reveal its potential for impacting the applied life sciences through its academic and research programs.

In KGI’s next 10 years, we will build upon our “Bold New Hybrid” admissions campaign and embark on new initiatives to expand the size and nature of our student body, creating an annual enrollment of 300 by 2017. Professionals in the industry seeking graduate education will be afforded the opportunity to attend KGI on a part-time basis, complementing the presence of full-time students in our Master of Bioscience (MBS) program. The inclusion of more students with significant work experience will improve the quality of team projects and other interactive aspects of the MBS program. KGI also will embark upon an initiative to establish new research centers dedicated to translational development. Representing a vital connection between the lab and the marketplace, translational development serves as a bridge for new scientific discoveries to become commercialized. KGI is primed to become a hub for applied innovation through new research centers modeled after the Amgen Bioprocessing Center. These new centers will come about through strategic partnerships that KGI will forge with industry groups, other universities, research institutes and philanthropic organizations dedicated to helping bring about biotechnology solutions in the 21st Century.

KGI is already hard at work to fulfill the promise of our next decade. As of June 30, KGI already has raised $18.5 million to meet the $30 million challenge from the W.M. Keck Foundation (see Keck Match Update, p. 14). The KGI Board of Trustees has provided significant support in helping meet this challenge, and soon the board will be in an even stronger position to assist KGI. By 2010, KGI plans to double the size of its board of trustees from what it was in 2005, bringing the grand total on our board to 30 members. With the addition of 18 new board members during this five-year span, KGI will have added a significant group of professional individuals to what is already a hands-on, high-performing team of trustees possessing a breadth and depth of knowledge and experience that is helping guide this thriving institution.

I know I am not alone in the feeling of excitement that surrounds KGI’s future, and I trust you too will feel the same way about this marvelous venture in higher education. As a healthcare venture capitalist, I found myself staring at the most exciting proposal for a start-up I had ever seen. I was hooked.

Chairman of the Board Robert E. Curry

KGI’S BOARD OF TRUSTEES consists of visionary leaders in business, industry and education who have guided the formation of KGI since its founding in 1997. In 2006-07, the board elected four new members, bringing the total to 22 regular members and eight emeriti trustees. The four new members—Bernard E. Kury, Catherine M. Burzik, Anthony D. Caracciolo, and Peter Barton Hutt—bring a wealth of knowledge and experience in fields ranging from law to pharmaceuticals to medical technology that will further enrich KGI’s expertise as an educational leader in the biosciences.

Peter Barton Hutt
Senior Counsel, Covington & Burling LLP
Elected June 2007
Known in legal circles as “the dean of the food-and-drug bar,” Peter Hutt brings considerable experience and depth of knowledge in fields ranging from law to pharmaceuticals to medical technology that will further enrich KGI’s expertise as an educational leader in the biosciences. As a healthcare venture capitalist, I found myself staring at the most exciting proposal for a start-up I had ever seen. I was hooked.

Peter Barton Hutt
Senior Counsel, Covington & Burling LLP
Elected June 2007
Known in legal circles as “the dean of the food-and-drug bar,” Peter Hutt brings considerable knowledge about the FDA process to KGI. He has been with Covington & Burling since 1960, except for the four years he worked as chief counsel for the FDA during 1971-1975. He is also no stranger to the classroom, having taught food and drug law at Harvard Law School since 1994 and at Stanford Law School in 1998.

Catherine M. Burzik
Chief Executive Officer, Kinetic Concepts, Inc.
Elected April 2007
Catherine Burzik possesses great appreciation for higher education, creating her own schooling in helping her climb through the executive ranks of Eastman Kodak and Johnson & Johnson. Since November 2006, Burzik has served as CEO of Kinetic Concepts, a global medical technology company. Before that she served as president of Applied Biosystems, a unit of Applera Corporation, and as president of Ortho-Clinical Diagnostics, a Johnson & Johnson Company.

Anthony D. Caracciolo
Senior Vice President for Manufacturing Operations, Gilead Sciences
Elected May 2006
Anthony Caracciolo can dispense like few others. When it comes to the pharmaceutical trade, Anthony Caracciolo dispenses knowledge like no other. He has been with Gilead Sciences since 1990, except for the years he served as CEO of Kinetic Concepts, a global medical technology company. Before that he served as president of Applied Biosystems, a unit of Applera Corporation, and as president of Ortho-Clinical Diagnostics, a Johnson & Johnson Company.

Bernard E. Kury
Senior Vice President for Manufacturing Operations, Guidant Corporation
Elected October 2006
Bernard Kury is the man to ask. For more than 20 years, Kury presided over Guidant and its predecessor companies, mostly as outside counsel while serving as a partner in the New York-based law firm of Dewey Ballantine, LLP. When he joined Guidant in 2006, he served as a key advisor to Guidant’s senior leadership on numerous issues, including the completed merger with Boston Scientific.
2006-07 PIONEER FUND CO-CHAIRS
John D. BaldeSchwieler
Member, Board of Trustees
Professor Emeritus of Chemistry, California Institute of Technology
Catherine L. Farrell
Member, Advisory Council
Executive Director of Global Clinical Supply
Chair, Management, Amgen, Inc.
Axa L. Cordle
Alumnus, MBS Class of 2006
Technology Development Associate
Alumnus, MBS Class of 2004
Chain Management, Amgen, Inc.

PRESIDENT’S CIRCLE | $10,000 TO $24,999
Daniel Bradbury
Richard and Deborah McConnell (The Richard and Deborah McConnell Family Foundation)
Cliff and Judith Milfar (Shameck Holding of California, Inc.)
Donald O’Neal
Arthur D. Riggs
Henry and Gayle Riggs
Jack and Jill Stark
Daniel and Dianna Vapnek (Fidelity Investments Charitable Gift Fund)

PIONEER | $5,000 TO $9,999
T. Gregory and Cynthia Dewey
Judith Healy
The Kenneth T. and Eileen L. Norris Foundation
Alice Kane and John Peterson
James Paul Lower (W.M. Keck Foundation)
Heather and Anne Ryan (W.M. Keck Foundation)
Selden M. Shulman
Russell and Joanna Smith (The H. Russell Smith Foundation)
Kueang-t and Ellen Yu (United Way of Greater Los Angeles)

PATRON | $2,500 TO $4,999
John Glanville
Paul Christ
Diana Walker (United Way of Greater Los Angeles)

BENEFACOR | $1,000 TO $2,499
Bonnie Arneson
Deb and Rubul Chakravarti
Gary Cohen
James and JoanCraig
Matthew and Kathryn Crouch
Catherine Farrell
Robert and Botte Finngarn
Weaver Gaines

GIFT$ 2006-2007 The Pioneer Fund

We are pleased to acknowledge the donors whose generous gifts to the Pioneer Fund helped further KGI’s mission of excellence in science education and research. We recognize these donors for their support of KGI and its students.

John D. Baldeschwieler and Marlene Konnar (The John D. Baldeschwieler and Marlene Konnar Foundation)
Anonymous
John Bak
John McNamara MBS ’07
Kathryn Auble MBS ’02
Padma Arunachalam MBS ’05
Kathryn Auble MBS ’02
Jack Austin MBS ’07
Prasad Babu MBS ’04
John B. K.
Diana Bartlett and John Milton
Armir Blace MBS ’03
Dan Baur
Randy and Rachel Bardhotz
Sharlee Blon MBS ’04
Heather Gill MBS ’04
Mark and Tina Booth
Noel Drinkerhoff and Alphonse Mead
Catherine Brown
Syd and Cathleen Brenn
Ralph and Julieta Cegilas
Robert Ceraglia
Steven and Kornelia Casper
Garth Chin
Sunun Chan
Asia Chang MBS ’07
Calinan MBS ’05 ’07
Joy Chin MBS ’07
Li Chen MBS ’07
Ava Cordle MBS ’06
Sara Emily Crew MBS ’03
Polina Dalovata MBS ’06

Maria D’Alessandro MBS ’03
Joshua Der MBS ’02
Kalpana Dasgupta MBS ’04
Maha Rudrahattan and Harsh Dhurvari MBS ’02
Marc Dobbie MBS ’02 and Joan Falzone Doba MBS ’02
Jeffrey Dack MBS ’07
Robert and Tracy Develer
Norman Ekstein and Tracy Kahn
Vincent Eng MBS ’07
Barbara and Tim Erwin
Kristine Florio MBS ’03
Nathaniel Freund MBS ’07
Susan Friedman and Stuart Baur
Tom Friedman MBS ’07
Jose Garcia
Jeffrey Graybiel MBS ’02
Adam Dorea MBS ’02
Gretchen Honeckes
Justin Hasek MBS ’07
Sandep Jeon MBS ’05
Chen Chen Xan and Jing-xuan Yeo
Mayfree Karandikar MBS ’07
Alexander Kelley P ’05
Jay Kelley MBS ’07
Laura and Don Kubec
Sandip Kumar
Arun and Hasu Lad P ’07
Sandep Lad MBS ’07
Jaimie Lee MBS ’02
Matthew Lee MBS ’07
James and Frances Lehman
Thomas W. Lester MBS ’04 and Suzanne R.
Kosian MBS ’04
Daren Levy MBS ’05
Courtney A. Levy
Jeff Lippman MBS ’07
Helen Liu MBS ’07
Melissa Louis MBS ’05
Gail Maderis
John and Elizabeth Maugure
Love Martinson MBS ’02
Maria Doroone and Anne McLaughlin
John McNamara MBS ’07
Ivan and Christine Mckel
Jonathan Mein MBS ’04
James and Helen Melman P ’07
Rachel Melman MBS ’07
Adam Miller MBS ’07
Reza Miragha
Karan and James Moynihan
Ali and Mitra Nadim
Robert Barger and Angela Nien
Anthony Ovula

Bruce Orman (Pioneer Hi-Bred International, Inc.)
Branchy Patri
Ryan Peeler MBS ’07
Andrew Phillips MBS ’06
Tran Pham MBS ’02
Joseph and Jean Platt
Luuke Powers MBS ’07
Sethfil Purushothaman MBS ’07
Thomas Quirk MBS ’07
Arun Ran MBS ’07
Animashaun and Sumbah Ray
Matt Reed and Marxxa Renier
William Roberts
Mark and Elizabeth Power Robinson
John Rogers
David Sadava
Cheryl Greene MBS ’04 and Christopher
Salmun MBS ’04
Molly Schick
Kathleen Schick and Titus Neumann
Leonore Schutz P ’08
Lowell Sears
Gary Silver MBS ’03
Luella Sequerra MBS ’02
Prachi MBS ’02 and Chirat Shah
Elzam and Virginia Shemely MBS P ’07
Kerry ann Shenney MBS ’07
Brandon and Marline Singleton
Christine Stopler
Thomas Smart
Daisy Sporgan P ’08
Theresa Stennes MBS ’03
Laura Sturr
Brian Sullivan
Kiran Soorarais MBS ’04
Anna Tate P ’07
Eric Tate MBS ’04
Michael Tancer MBS ’04
Robert Tapella MBS ’07
David and Jane Tarbell
Diane Taylor
Peter Vandeventer
Vidya Vasavada MBS ’05
Wang Wang MBS ’02
Mason Werner
Mary and Steven Weiss from Steven
Weslake MBS ’03
Susan Wessler
Joseph and Mary Wil P ’02
Chester Wong MBS ’07
Bruce and Susan Worster
Kiril Lynn Zbars MBS ’02

618980628 for FY 2006-2007. Over 50% of gifts to the Pioneer Fund are specifically designated for scholarship aid, thereby helping to educate the best and brightest students for leadership in the life sciences industry.
FOR KGI STUDENTS Chris Warner and Peter Vandeventer, their research to combat the threats of bioterrorism won them honors that no other KGI—or Claremont College—student had ever received: a SMART scholarship.

SMART, short for Science, Mathematics and Research for Transformation, is a program funded by the U.S. Department of Defense (DoD) that supports the education and recruitment of undergraduate and graduate students in the fields of science, technology, engineering and mathematics. Warner and Vandeventer, the first KGI students to apply for the scholarship, were among 100 winners selected from a nationwide pool of 1,600 applicants.

KGI President Sheldon Schuster, PhD, was overjoyed when he heard the news. "This is a proud day for KGI," he said. "To have overjoyed when he heard the news. "This is a proud day for KGI," he said. "To have two first-time recipients of this scholarship, each will receive a stipend of up to $38,000, full tuition reimbursement and a book allowance of $1,000. Also, each scholar is required to work for the DoD for a period of time equal to the length of their scholarship support.

Vandeventer is grateful for the scholarship support and the opportunity KGI has given him. "If it was not for KGI, I would not have received this scholarship," he said. "KGI has offered me many opportunities. It’s been a worthy investment, and one of the best I’ve ever made."

Vandeventer, who also received a Weingart Foundation scholarship in 2006-07, will begin his PhD studies upon completing his Master of Bioscience degree in December and prepare biological samples for DNA detection as part of a project at KGI to develop a handheld device that can detect biological or chemical pathogens. Likewise, Warner will pursue his PhD at KGI after finishing his MBS next spring and will begin working on ways to reduce exposure to deadly diseases released by terrorists.

"Right now, if there is an epidemic, it takes six months before the earliest vaccine would be available," Warner explained. "I'm looking at short-term prevention, developing systems that could mass produce antibiotics and make them available."

While they conduct their research, neither Warner nor Vandeventer will have to worry about living expenses, tuition, or employment after graduation. As SMART scholars, each will receive a stipend of up to $38,000, full tuition reimbursement and a book allowance of $1,000. Also, each scholar is required to work for the DoD for a period of time equal to the length of their scholarship support.

Vandeventer is grateful for the scholarship support and the opportunity KGI has given him. "If it was not for KGI, I would not have received this scholarship," he said. "KGI has offered me many opportunities. It’s been a worthy investment, and one of the best I’ve ever made."

"Right now, if there is an epidemic, it takes six months before the earliest vaccine would be available," Warner explained. "I'm looking at short-term prevention, developing systems that could mass produce antibiotics and make them available."

While they conduct their research, neither Warner nor Vandeventer will have to worry about living expenses, tuition, or employment after graduation. As SMART scholars, each will receive a stipend of up to $38,000, full tuition reimbursement and a book allowance of $1,000. Also, each scholar is required to work for the DoD for a period of time equal to the length of their scholarship support.

Vandeventer is grateful for the scholarship support and the opportunity KGI has given him. "If it was not for KGI, I would not have received this scholarship," he said. "KGI has offered me many opportunities. It’s been a worthy investment, and one of the best I’ve ever made."

"Right now, if there is an epidemic, it takes six months before the earliest vaccine would be available," Warner explained. "I'm looking at short-term prevention, developing systems that could mass produce antibiotics and make them available."

While they conduct their research, neither Warner nor Vandeventer will have to worry about living expenses, tuition, or employment after graduation. As SMART scholars, each will receive a stipend of up to $38,000, full tuition reimbursement and a book allowance of $1,000. Also, each scholar is required to work for the DoD for a period of time equal to the length of their scholarship support.
As developments in biotechnology grow not only nationally but internationally, the industry faces increasing scrutiny by human rights advocates and ethicists. Questions continue to arise, such as: Does the American pharmaceutical industry have an ethical responsibility to the poor in developing nations? Will the biotech revolution alter the very definition of “human?”

These questions and others served as the focus of KGI’s Bioethics Symposium 2007, “Biotechnology and Human Rights: Industry’s Responsibility?” Organized by Gary Cohen, KGI’s Jacobs Visiting Professor of Biotechnology Law and Ethics, the day-long symposium brought together renowned academics and corporate leaders to debate before a large audience that included KGI students—the future leaders of biotechnology.

Cohen invited a dozen experts to participate in the symposium, including Professors Alexander Capron, USC Gould School of Law, Gregory Stock, UCLA School of Public Health, and Stephen Marks, Harvard School of Public Health, and from the corporate sector Lisa Conte, founder and CEO of Napo Pharmaceuticals, Inc., whose mission is to provide affordable drugs for developing countries.

“This was a wonderful opportunity for us to collaborate with different leaders in the field,” said Cohen. “We deeply collaborated around tough questions and issues, and this is the way to do it. The whole purpose is provocation.”

A total of four panels addressed topics such as “The Corporation and its Obligations” and “Human Rights for Redesigned Humans.” Following individual presentations by each panelist, Cohen moderated coffee-table discussions between the experts who voiced countervailing arguments and fielded questions from the audience.

The most riveting debate occurred over what genetic engineering, nanotechnology and robotics may have in store for the human race and the principles of law and social values. Stock, an outspoken advocate of the biotech revolution, squared off against Marks, who expressed caution about the speed with which society should embrace biotech advances.

Brian Keeley, associate professor of philosophy at Pitzer College, who debated Stock and Marks on the same panel, pointed out that the debate was beneficial for those in attendance, especially KGI’s students.

“Part of the intention with the forum is based on who is in the audience,” Keeley said. “These types of decisions are what the students are going to be making in the future. They are going to have to confront them, and it’s better for it to hit them now while they’re in their 20s.”

KGI student Robert Tapella appreciated the opportunity to hear the pros and cons of the industry’s work and its implication. He said it was “important to be exposed to these types of things because these are issues that companies are facing”—companies that Tapella and other KGI graduates will be making critical decisions for some day.

On to Boston: The Debate Continued

Following the symposium at KGI, Professor Gary Cohen took the debate over biotechnology and human rights on the road and presented it before the world’s largest professional biotechnology body: the Biotechnology Industry Organization (BIO).

At BIO’s Annual International Convention in Boston, KGI hosted one of four “bioethics track” educational programs on the topic, “Biotechnology’s Responsibility for Human Rights?” Cohen chaired the panel that included George Annas, professor at the Boston University School of Public Health; Bernd Kasemir, founding director of sustainserv; Steven Holtzman, CEO and chairperson of Infinity Pharmaceuticals; Simon Best, chairperson of the UK BioIndustry Association; Finley Austin, policy director at Hoffmann-La Roche; and Jeffrey Elton, senior vice president of strategy and global chief operating officer at the Novartis Institutes for BioMedical Research.

The experts discussed topics that included corporate sponsorship of research involving humans, access to and affordability of biotech products and whether biotech companies have heightened obligations because they are part of the human health-care enterprise.

The 2007 BIO International Convention drew a record 22,366 attendees, a nearly 15 percent increase from the previous year, with representatives from 48 states and 64 countries.
Keck Match Update

IN MARCH 2005, the W.M. Keck Foundation awarded KGI a munificent $20 million matching grant. The grant is intended to leverage additional support from a variety of donors and thus fuel KGI’s continued growth. According to the terms of the grant, KGI has seven years to meet the $30 million matching requirement. As of June 30, 2007, a total of $18,471,998 has been raised towards the match. For a young institution, this is quite an accomplishment—one that speaks to the strong commitment and generosity of KGI’s donors. It is this support that is helping to build KGI’s endowment, securing funds for future generations of KGI students and faculty to come.

THE KGI ADVISORY COUNCIL consists of leaders from biotech, pharmaceutical, medical device and agricultural biotechnology companies who provide industry insight, marketplace feedback and support for KGI’s corporate outreach.

Bruce Alberts, PhD, Professor, University of California, San Francisco
Bonnie Anderson, Consultant
Gary Augusta, Executive Director, OCTAna
Luis J. Berga, Chief Executive Officer, Luis Berga & Associates, Inc.
Randy Berholtz, Vice President, General Counsel, Secretary, AGON Laboratories
Rolando Brewer, PhD, Director of Business Development, Invitrogen
Linda Castle, PhD, Research Coordinator, Pioneer Hi-Bred International, Inc.
Stephen G. Daggett, PhD, Director, Product Support, R&D, Online Diagnostics
Catherine L. Farrall, PhD, Executive Director, Global Clinical Supply Chain Management, Amgen, Inc.
Jay T. Flatley, President and Chief Executive Officer, Illumina, Inc.
Weaver Gaines, Founder and Managing Director, Americas Biotech Distributor
Sean R. Gallagher, PhD, Chief Technology Officer, Ultraworld Products, Inc.
Larry Gold, PhD, Founder, Chief Executive Officer and Chairman, Semalogix, Inc.
Paul C. Grindt, MD, Chief Medical Officer, Kalypsys, Inc.
Ross A. Grossman, PhD, Vice President, Human Resources, Regeneron Pharmaceuticals, Inc.
Kenneth J. Graus, PhD, Site Director, Calygen LLC [a Mansanto Company]
Richard Hamilton, PhD, President and Chief Executive Officer, Ceres, Inc.
When Beckman Coulter, Inc. is one of KGI's most important and longstanding partners, I can’t say enough about the positive impact that Beckman Coulter has had on KGI,” said Diana Bartlett, KGI’s director of corporate partnerships.

Beckman Coulter has sponsored six Team Masters Projects (TMPs), with a seventh implemented for 2007-08. Representing the company’s commitment to the success of the school for educating scientists to tackle real-world problems with the help of KGI faculty and corporate liaisons, Beckman Coulter also has hired 17 KGI students for summer internships, and in November 2006, the company donated a $300,000 micro-fluidics machine (Biomek® FX) to KGI’s bioengineering laboratory.

The Biomek® FX provides opportunities for students to gain hands-on understanding of the hardware and software challenges involved with high throughput technology. KGI faculty also have benefited from using the instrument in conducting basic research involving nucleic acids, proteins and polymers for use in drug discovery, medical diagnostics and medical device applications.

“She could not be more pleased with the results,” said Beckman Coulter, Inc. “Our Biomek® FX provides opportunities for students to gain hands-on understanding of the hardware and software challenges involved with high throughput technology. KGI faculty also have benefited from using the instrument in conducting basic research involving nucleic acids, proteins and polymers for use in drug discovery, medical diagnostics and medical device applications.”

Beckman Coulter was pleased to donate a Biomek® automation system to KGI, said Jim Widgren, corporate vice president for Asia Pacific and Latin America operations and a member of the KGI Advisory Council. “We support the goals of KGI to educate future leaders in the life sciences industry.”

**GILEAD SCIENCES**

Corporate executives have discovered a wealth of advantages from helping KGI with its academic and research programs, making the corporate partnerships a win-win for everyone involved. For instance, Gilead Sciences, a biopharmaceutical company, sent six of its scientists to attend a KGI pilot program, “Business Basics for Scientists,” designed to help technical and operations leaders learn more about accounting and finance, business decision-making and management. Anthony Caracazlo, senior vice president for manufacturing and operations at Gilead Sciences and newly-elected member of the KGI Board of Trustees, was pleased with the results.

“As our company and the complexity of our business grew, we recognized the importance of providing our workforce with educational opportunities that increase business acumen and management skills,” said Caracazlo. “KGI is uniquely positioned to deliver programs that integrate business skills with the realities of the dynamic biotechnology and life science industry.”

When it comes to TMPs, Gilead has sponsored three projects in just the last two years and two more for 2007-08. “The Team Masters program is a great benefit to the success of our business process and key operational projects,” said Caracazlo. “The TMP has also become a valuable pool of new, highly talented recruits for Gilead’s workforce.”

**ALLEURE**

Design and Implement a Reliable High-Throughput Screening Method to Identify Compounds with Potential to Treat Immunological Disorders (2005-06)

**AMGEN, INC.**

Evaluation of Plastic Pre-made Vials for Packaging Therapeutic Proteins Part 2 (2006-07)

**APPLIED BIOSYSTEMS**

“Judy Lab” A Genomics Education Product Line (2006-07)

Affinity Reagents (2006-07)

**ARTERIAL LIGHT SCIENCE**

Develop Business Plan for Wearable, Non-invasive Patch Designed to Increase Blood Flow in Heart Muscle (2005-06)

**BECKMAN COULTER, INC.**

Customer and Business Validation for Development of Molecular Diagnostic Testing (2006-07)

**BIOMETrix®**

Commericalization Strategy of BxHL: Test for Diabetes 2005-06

Microarray from Research Fire Disease Arrays, Identify Therapy Status, IP Issues, Competition (2005-04)

Conduct Market Assessments to Identify Unmet Needs in Bioscience (2004-05)

Analyze the SNPs Diagnostic Market (2001-02)


**BIOCATALytics**

Diagnostic Inferences (2005-06)

Assay Methods for Monitoring and Treatment of Cystinuria (2005-06)

**BIOMEK®**

Commercialization of a Real-time Compact Isothermal Fluor/emorescence Reader (2006-07)

**CERES**

Development of Marker Systems for Selected CereS (2004-05)

**CHILDREN’S HOSPITAL LOS ANGELES**

Identify Methods of Tissue and Organ Regeneration (2004-05)

**CLEAR SPRINGS LAND COMPANY LLC**

Adaptive Venues and Artificial Intelligence Systems (2005-06)

Assessment of Proton Beam Therapy, Potential Medical Impact, and Financial Requirements (2004-05)

**DOW ASIReScIENCES**

Develop and Optimize CMO Testing Method (2006-07)

**EGOGEN**

Assess and Validate Computational Procedures used for Generating Three Dimensional Models of Ligands (2002-03)

**EGUIReSEARCH**

Assess & Build SmartCard: Device that Provides Therapists with Feedback on Effectiveness of Training Regimes, Horse Health (2003-04)

**GENOMATICA**

Create Genome Scale Metabolic Model of Pedia Pensthor (2003-04)

**GILEAD SCIENCES**


**HALLMARK INNOVATIONS**

Create a Semi-automated Process for the Creation of Rapidly Degradable Materials (2006-07)

**HEALTHq**

Conduct strategy technology scouting in biotechnology (2004-05)

**HEALTHq INNOVATION**

Design a Cost-efficient, Practical Assay to Differentiate and Identify 100K Elements on a Microarray (2001-02)

**INVENTRO**

Forecasting and Capacity Planning for Functional Genomics Services (2005-06)

**IONIAN TECHNOLOGIES**

Optimize Nucleic Acid Detection Assay (2002-03)

**KECK GRADUATE INSTITUTE (KGI)**

Design a Process for Introduction or Modification of Specific Gases by Homologous Recombination (2001-02)

**Laser GENERATION of CARtiLAGE**

Analyze Market for Laser Technology that Regenerates Cartilage in Destroyed and Damaged Spinal Discs (2005-04)

**LEGENDARY MEDICAL INFORMATION SYSTEMS**

Validate Software Methodology for Hereditary Cancer Risk Assessment, Compositional MMR (2003-04)

**LINK RESEARCH**

Commercialization of Social Network Analysis Capability (2006-07)

**MANG3STREAM**

Develop and Validate Novel Methods for Peptide and Protein Separations Using a Microfluidic Continuous Flow Technique and Analytical High Pressure Liquid Chromatography (2003-04)

**MINDS+**

Identify Enzyme Assays that are Pharmacologically Relevant (2002-03)

**NORTHROP GRUMMAN**

Novel Sample Preparation Technologies for Rapid Identification of Pathogenic Organisms (2006-07)

**ORTHO-CLINICAL DIAGNOSTICS**

Market Assessment of Ion Depositors for the Calibration of Automated Diagnostic Test Systems (2006-07)

**PIONEER HI-BRED**

Assess High Throughput Multiplex EXPAR-SNP Detection for Corn Genotyping (2004-05)

**PIONEER HI-BRED**

Optimise Conditions for Using Oligonucleotide Amplification System to Help Characterize and Optimise Modifications in Corn and Other Plants (2003-04)

**RIVERDALE**

Develop a Scalable Database to Store and Analyze the Pichia Pastoris Genome (2002-03)

**ULTRAVIOLET PRODUCTS**

Develop Novel Technologies for In Vivo Imaging to Provide Shadowless Uniform Illumination of Irregularly Shaped Convex Objects (2004-05)

**ULTRAVIOLET PRODUCTS**

Develop Software/Hardware for Image Acquisition and Analysis of Susceptible Protein and Peptide Separation Results (2003-04)

**WORCS, INC.**

Develop a New Plan for Waters’ New MALDI Analysis System (2002-03)

**ZIYZER PHARMACEUTICALS**

Utilize Zierler’s Tools and Databases to Discover Novel Molecular Targets for Two Infectious Diseases (2002-03)

Create a Semi-automated Process for the Investigation of Novel Protein Interactions in the General Pathogenesis of Tumors and Alzheimer’s Disease (2001-02)

Create a Validated Database of Protein Interactions Used in Drug Discovery (2001-02)
The Amgen Bioprocessing Center Advisory Board (ABCAB) consists of scientists, engineers, academics and corporate executives who provide support and advice to KGI’s Amgen Bioprocessing Center.

AMGEN BIOPROCESSING CENTER ADVISORY BOARD

Dawn R. Applegate, PhD
President and Chief Executive Officer, RegeneMed, Inc.

Mark Applegate, PhD
Senior Director, Operations, Favrille, Inc.

John Aunins, PhD
Executive Scientific Director, Vaccine Bioprocess R&D, Merck & Co. Inc.

Harvey Blanch, PhD
Professor, Chemical Engineering, University of California at Berkeley

Fabrizio Bonanni, PhD
Executive Vice President, Operations, Amgen Inc.

Anthony Bright, PhD
Engineering Department, Harvey Mudd College

Manuel Carrodeguas, PhD
Professor and Chief Executive Officer, IBET

David Chang, PhD
Director of Process Research & Development, Genentech, Inc.

Charles L. Cooney, PhD
Professor, Department of Chemical Engineering and Faculty Director, Massachusetts Institute of Technology

Larry A. Couture, PhD
Senior Vice President, Technology Development, Beckman Research Institute, City of Hope National Medical Center

Iman Famili, PhD
Associate Director, Computational Modeling, Genomatica, Inc.

Joydeep Goswami, PhD
Vice President, Stem Cells & Regenerative Medicine, Invitrogen

S. Sam Guhan, PhD
Executive Director, Process and Analytical Sciences, Amgen Inc.

Robert Kiss, PhD
Director of Late Stage Cell Culture (LSCC) Department, Genentech, Inc.

James Leung, PhD
Vice President of Biotechnology, Ipsen

Karen McDonald, PhD
Associate Dean of Research and Graduate Studies, University of California at Davis

Steven Perry
Vice President of Manufacturing Operations, Cytochrome Biologics

Brandon Price, PhD
President, Falcon Ridge Associates

Tom Reed
Vice President of Finance and Corporate Development, Genomatica, Inc.

Christoph Adami, PhD
Professor: Computational and Evolutionary Biology, Bioinformatics, Artificial Life, Neural Systems

Brian Adderley, PhD
Assistant Professor: Physiological Control, Optimization of Plant Genes, Genomics and Metabolic Networks

David Vetterlein, PhD
Vice President, Process Development & Manufacturing, Eli Lilly/ICOS Corporation

Dennis M. Fenton, PhD
Professor: Bioengineering, System Theory, Medical Devices, Business Ethics

Steven N. Cooper, PhD
Associate Professor: Management, Biotechnology Cluster, Corporate Governance, Director of the MSB Program

Deb N. Chakravarti
Research Associate; Professor: Immunology, Protein Biochemistry, T-cell Signaling, Mass Spectrometry

T. Gregory Dewey, PhD
Senior Vice President for Academic Affairs, Dean of Faculty, and Robert E. Finninger Professor of Applied Life Sciences

T. Gregory Dewey, PhD
Professor of Recombinant Proteins, Pichia pastoria, Gene Expression, Parasite Biogenesis

Matthew S. Crouch, PhD
Professor: Mechanisms of Infection, Antibiotics, High Throughput Screening, Protein Structure, Disease Models of Infection

Kathrin Schirick, PhD
Research Assistant Professor: Sterol Biosynthesis Genes, Plant Sterols, Lipids, Sterol Signaling, Plant Development

Sheldon M. Schuster, PhD
Professor: Plant Genetics, Plant Regeneration, Plant Breeding

Dennis M. Fenton, PhD
Executive Vice President, Amgen, Inc.

Mai Subramanian, PhD
Director, Center for Biotechnology & Bioprocessing, University of Iowa

Rob Tenerowicz
Vice President of Operations, KODA

Steven W. Casper, PhD
Professor, Warwick Systems Biology Centre

Sheldon M. Schuster, PhD
Professor of Plant Biology, University of California, Riverside

Susan M. Jerian, MD
President, OncRD, Inc.

John Milton, MD, PhD
Kan Chair, Computational Neuroscience, Joint Science Department, The Claremont Colleges

Craig L. Pearce, PhD
Associate Professor of Management, Peter F. Drucker and Mahatma Gandhi College of Management

Steve C. Wheelwright, PhD
Professor: Plant Genomics

ANAPLEX BIOSCIENCES

Dawn R. Applegate, PhD
President and Chief Executive Officer, RegeneMed, Inc.

Dawn R. Applegate, PhD
President and Chief Executive Officer, RegeneMed, Inc.

Chen Chan Kan, PhD
Research Professor: Drug Discovery, High Throughput Screening, Protein Structure, Proteasomes

Karen L. Meynihan, PhD
Associate Professor: Liposomes, Drug Delivery Systems

Al Nahim, PhD
Professor: Biotechnology, Microfluidics, Nanotechnology, Electrowetting, Mathematical Modeling

Angelika Niemi, PhD
Assistant Professor: Self-assembly and Molecular Recognition in Biological and Man-made Systems

M. Ian Phillips, PhD, DSC
Norris Professor of Applied Life Sciences: Biology of Stem Cells, Gene Regulatory Networks

Alpan Raval, PhD
Assistant Professor: Mathematical Modeling, Genome Analysis, Protein Structure, Sequence Alignment

Animash Ray, PhD
Professor and Director of the MBX-PhD Program: Gene Function, Gene Regulatory Networks, DNA Repair, Gene Targeting, Gene Expression, Computer Science

J. David Wheelwright, PhD
Professor: Entrepreneur-in-Residence and Director of Research: Anti-infectious Drug Discovery, Antibiotics, High Throughput Screening, Microbial Genomics, Animal Models of Infection

Kathrin Schirick, PhD
Research Assistant Professor: Sterol Biosynthesis Genes, Plant Sterols, Lipids, Sterol Signaling, Plant Development

Sheldon M. Schuster, PhD
Professor: Plant Genetics, Plant Regeneration, Plant Breeding

Tissue Engineering

Yao Liang Tang, PhD
Research Associate Professor: Biology of Mycoplasma in Cancer

David Wild, PhD
Professor, Warwick Systems Biology Centre

James D. Sterling
President and Professor: Mechanisms of Disease, Gene Regulatory Networks, DNA Repair, Gene Targeting, DNA Delivery Systems

Michael S. Waterman, PhD
Professor of Mathematics, Biological Sciences and Computer Science, University of Southern California: Computational Biology

Susan R. Wesslar, PhD
Distinguished Researcher and Regents Professor of Biology, University of Georgia, Howard Hughes Medical Institute Professor: Plant Genetics

Steven C. Wheelwright, PhD
Edval Bryant Ford Professor of Administration, Smithwick, Harvard Business School: Technology and Operations Management

ADJUNCT AND VISITING FACULTY

Phil Barnett, PhD
California Institute of Technology, Jet Propulsion Laboratory (Retired)

Norman C. Elstrand, PhD
Professor of Genetics, University of California, Riverside

David Essayan, MD
OncoRD, Inc.

Darren Fizex, PhD
Associate Professor of Economics, Department Chair, Claremont Graduate University

Alan R. Rothfield, MD
Critical Care Medicine, Internal Medicine, Pulmonary

David L. Wild, PhD
Research Professor, Keck Graduate Institute; Warwick Systems Biology Centre

PROFESSORS-AT-LARGE

David E. Selker, PhD
Prater Family Foundation Professor of Biology, Joint Science Department, The Claremont Colleges: Biology of Cancer, Drug Resistance in Cancer

Michael S. Waterman, PhD
Professor of Mathematics, Biological Sciences and Computer Science, University of Southern California: Computational Biology

Phil Barnett, PhD
California Institute of Technology, Jet Propulsion Laboratory (Retired)

Norman C. Elstrand, PhD
Professor of Genetics, University of California, Riverside

David Essayan, MD
OncoRD, Inc.

Darren Fizex, PhD
Associate Professor of Economics, Department Chair, Claremont Graduate University

Susan M. Jerian, MD
President, OncRD, Inc.

John Milton, MD, PhD
Kan Chair, Computational Neuroscience, Joint Science Department, The Claremont Colleges

Craig L. Pearce, PhD
Associate Professor of Management, Peter F. Drucker and Mahatma Gandhi College of Management

Steve C. Wheelwright, PhD
Professor: Plant Genomics

ANAPLEX BIOSCIENCES

Dawn R. Applegate, PhD
President and Chief Executive Officer, RegeneMed, Inc.

Chen Chan Kan, PhD
Research Professor: Drug Discovery, High Throughput Screening, Protein Structure, Proteasomes

Karen L. Meynihan, PhD
Associate Professor: Liposomes, Drug Delivery Systems

Al Nahim, PhD
Professor: Biotechnology, Microfluidics, Nanotechnology, Electrowetting, Mathematical Modeling

Angelika Niemi, PhD
Assistant Professor: Self-assembly and Molecular Recognition in Biological and Man-made Systems

M. Ian Phillips, PhD, DSC
Norris Professor of Applied Life Sciences: Biology of Stem Cells, Gene Regulatory Networks

Alpan Raval, PhD
Assistant Professor: Mathematical Modeling, Genome Analysis, Protein Structure, Sequence Alignment

Animash Ray, PhD
Professor and Director of the MBX-PhD Program: Gene Function, Gene Regulatory Networks, DNA Repair, Gene Targeting, DNA Delivery Systems

J. David Wheelwright, PhD
Professor: Entrepreneur-in-Residence and Director of Research: Anti-infectious Drug Discovery, Antibiotics, High Throughput Screening, Microbial Genomics, Animal Models of Infection

Kathrin Schirick, PhD
Research Assistant Professor: Sterol Biosynthesis Genes, Plant Sterols, Lipids, Sterol Signaling, Plant Development

Sheldon M. Schuster, PhD
Professor: Plant Genetics, Plant Regeneration, Plant Breeding

Tissue Engineering

Yao Liang Tang, PhD
Research Associate Professor: Biology of Mycoplasma in Cancer

David Wild, PhD
Professor, Warwick Systems Biology Centre

James D. Sterling
President and Professor: Mechanisms of Disease, Gene Regulatory Networks, DNA Repair, Gene Targeting, DNA Delivery Systems

Michael S. Waterman, PhD
Professor of Mathematics, Biological Sciences and Computer Science, University of Southern California: Computational Biology

Susan R. Wesslar, PhD
Distinguished Researcher and Regents Professor of Biology, University of Georgia, Howard Hughes Medical Institute Professor: Plant Genetics

Steven C. Wheelwright, PhD
Edval Bryant Ford Professor of Administration, Smithwick, Harvard Business School: Technology and Operations Management

ADJUNCT AND VISITING FACULTY

Phil Barnett, PhD
California Institute of Technology, Jet Propulsion Laboratory (Retired)

Norman C. Elstrand, PhD
Professor of Genetics, University of California, Riverside

David Essayan, MD
OncoRD, Inc.

Darren Fizex, PhD
Associate Professor of Economics, Department Chair, Claremont Graduate University

Susan M. Jerian, MD
President, OncRD, Inc.

John Milton, MD, PhD
Kan Chair, Computational Neuroscience, Joint Science Department, The Claremont Colleges

Craig L. Pearce, PhD
Associate Professor of Management, Peter F. Drucker and Mahatma Gandhi College of Management

Steve C. Wheelwright, PhD
Professor: Plant Genomics

ANAPLEX BIOSCIENCES

Dawn R. Applegate, PhD
President and Chief Executive Officer, RegeneMed, Inc.

Chen Chan Kan, PhD
Research Professor: Drug Discovery, High Throughput Screening, Protein Structure, Proteasomes

Karen L. Meynihan, PhD
Associate Professor: Liposomes, Drug Delivery Systems

Al Nahim, PhD
Professor: Biotechnology, Microfluidics, Nanotechnology, Electrowetting, Mathematical Modeling

Angelika Niemi, PhD
Assistant Professor: Self-assembly and Molecular Recognition in Biological and Man-made Systems

M. Ian Phillips, PhD, DSC
Norris Professor of Applied Life Sciences: Biology of Stem Cells, Gene Regulatory Networks

Alpan Raval, PhD
Assistant Professor: Mathematical Modeling, Genome Analysis, Protein Structure, Sequence Alignment

Animash Ray, PhD
Professor and Director of the MBX-PhD Program: Gene Function, Gene Regulatory Networks, DNA Repair, Gene Targeting, DNA Delivery Systems

J. David Wheelwright, PhD
Professor: Entrepreneur-in-Residence and Director of Research: Anti-infectious Drug Discovery, Antibiotics, High Throughput Screening, Microbial Genomics, Animal Models of Infection

Kathrin Schirick, PhD
Research Assistant Professor: Sterol Biosynthesis Genes, Plant Sterols, Lipids, Sterol Signaling, Plant Development

Sheldon M. Schuster, PhD
Professor: Plant Genetics, Plant Regeneration, Plant Breeding

Tissue Engineering

Yao Liang Tang, PhD
Research Associate Professor: Biology of Mycoplasma in Cancer

David Wild, PhD
Professor, Warwick Systems Biology Centre

James D. Sterling
President and Professor: Mechanisms of Disease, Gene Regulatory Networks, DNA Repair, Gene Targeting, DNA Delivery Systems

Michael S. Waterman, PhD
Professor of Mathematics, Biological Sciences and Computer Science, University of Southern California: Computational Biology

Susan R. Wesslar, PhD
Distinguished Researcher and Regents Professor of Biology, University of Georgia, Howard Hughes Medical Institute Professor: Plant Genetics

Steven C. Wheelwright, PhD
Edval Bryant Ford Professor of Administration, Smithwick, Harvard Business School: Technology and Operations Management
For his study entitled: ‘The Marketplace for Ideas: Can Los Angeles Build a Successful Biotechnology Cluster?’ Casper will compare his findings on Los Angeles with San Diego. The contrast between the two Southern California cities is remarkable. Since 1981, only 36 biotech companies have been created in Los Angeles, while San Diego boasts 189 during the same time period.

The Haynes Foundation endorsed Casper’s research with its first-ever grant to KGI. Established in 1926, the foundation is the oldest private foundation in the city and is a leading supporter of academic research in the social sciences for Los Angeles. According to William Burke, the foundation’s administrative director, the foundation’s board believes that an intellectual inquiry like that proposed by KGI should yield objective data that will be of great value in the formation and discussion of the policy options for the L.A. area.”

Fletcher Jones Funds Non-Profit Opportunity

While many KGI graduates embark on careers with biotech companies, a growing number of students have shown interest in non-profit opportunities related to health care and research. Thanks to the latest grant from the Fletcher Jones Foundation, students will now have a new way of exploring whether a career in government or a non-profit organization is right for them.

The Fletcher Jones Scholars program will provide scholarship support to selected students who are interested in working, for instance, with the Food and Drug Administration, Centers for Disease Control, National Institutes of Health, City of Hope and Children’s Hospital in Los Angeles. In addition, the program provides funding to assist students with summer internships at a government or non-profit office and for related expenses.

The Fletcher Jones Foundation has been a supporter of KGI since its founding. In 1998, the foundation awarded KGI a $1 million founding grant to support infrastructure and furnishings. Two years later, KGI received a grant of $500,000 to support the recruitment and salaries of two Fletcher Jones Assistant Professors. That grant was followed in 2003 by an award of $250,000 for continued support of the Fletcher Jones Assistant Professors.

For his study entitled: ‘The Marketplace for Ideas: Can Los Angeles Build a Successful Biotechnology Cluster?’ Casper will compare his findings on Los Angeles with San Diego. The contrast between the two Southern California cities is remarkable. Since 1981, only 36 biotech companies have been created in Los Angeles, while San Diego boasts 189 during the same time period.

The Haynes Foundation endorsed Casper’s research with its first-ever grant to KGI. Established in 1926, the foundation is the oldest private foundation in the city and is a leading supporter of academic research in the social sciences for Los Angeles. According to William Burke, the foundation’s administrative director, the foundation’s board believes that an intellectual inquiry like that proposed by KGI should yield objective data that will be of great value in the formation and discussion of the policy options for the L.A. area.”

Fletcher Jones Funds Non-Profit Opportunity

While many KGI graduates embark on careers with biotech companies, a growing number of students have shown interest in non-profit opportunities related to health care and research. Thanks to the latest grant from the Fletcher Jones Foundation, students will now have a new way of exploring whether a career in government or a non-profit organization is right for them.

The Fletcher Jones Scholars program will provide scholarship support to selected students who are interested in working, for instance, with the Food and Drug Administration, Centers for Disease Control, National Institutes of Health, City of Hope and Children’s Hospital in Los Angeles. In addition, the program provides funding to assist students with summer internships at a government or non-profit office and for related expenses.

The Fletcher Jones Foundation has been a supporter of KGI since its founding. In 1998, the foundation awarded KGI a $1 million founding grant to support infrastructure and furnishings. Two years later, KGI received a grant of $500,000 to support the recruitment and salaries of two Fletcher Jones Assistant Professors. That grant was followed in 2003 by an award of $250,000 for continued support of the Fletcher Jones Assistant Professors.

For his study entitled: ‘The Marketplace for Ideas: Can Los Angeles Build a Successful Biotechnology Cluster?’ Casper will compare his findings on Los Angeles with San Diego. The contrast between the two Southern California cities is remarkable. Since 1981, only 36 biotech companies have been created in Los Angeles, while San Diego boasts 189 during the same time period.

The Haynes Foundation endorsed Casper’s research with its first-ever grant to KGI. Established in 1926, the foundation is the oldest private foundation in the city and is a leading supporter of academic research in the social sciences for Los Angeles. According to William Burke, the foundation’s administrative director, the foundation’s board believes that an intellectual inquiry like that proposed by KGI should yield objective data that will be of great value in the formation and discussion of the policy options for the L.A. area.”

Fletcher Jones Funds Non-Profit Opportunity

While many KGI graduates embark on careers with biotech companies, a growing number of students have shown interest in non-profit opportunities related to health care and research. Thanks to the latest grant from the Fletcher Jones Foundation, students will now have a new way of exploring whether a career in government or a non-profit organization is right for them.

The Fletcher Jones Scholars program will provide scholarship support to selected students who are interested in working, for instance, with the Food and Drug Administration, Centers for Disease Control, National Institutes of Health, City of Hope and Children’s Hospital in Los Angeles. In addition, the program provides funding to assist students with summer internships at a government or non-profit office and for related expenses.

The Fletcher Jones Foundation has been a supporter of KGI since its founding. In 1998, the foundation awarded KGI a $1 million founding grant to support infrastructure and furnishings. Two years later, KGI received a grant of $500,000 to support the recruitment and salaries of two Fletcher Jones Assistant Professors. That grant was followed in 2003 by an award of $250,000 for continued support of the Fletcher Jones Assistant Professors.

For his study entitled: ‘The Marketplace for Ideas: Can Los Angeles Build a Successful Biotechnology Cluster?’ Casper will compare his findings on Los Angeles with San Diego. The contrast between the two Southern California cities is remarkable. Since 1981, only 36 biotech companies have been created in Los Angeles, while San Diego boasts 189 during the same time period.

The Haynes Foundation endorsed Casper’s research with its first-ever grant to KGI. Established in 1926, the foundation is the oldest private foundation in the city and is a leading supporter of academic research in the social sciences for Los Angeles. According to William Burke, the foundation’s administrative director, the foundation’s board believes that an intellectual inquiry like that proposed by KGI should yield objective data that will be of great value in the formation and discussion of the policy options for the L.A. area.”

Fletcher Jones Funds Non-Profit Opportunity

While many KGI graduates embark on careers with biotech companies, a growing number of students have shown interest in non-profit opportunities related to health care and research. Thanks to the latest grant from the Fletcher Jones Foundation, students will now have a new way of exploring whether a career in government or a non-profit organization is right for them.

The Fletcher Jones Scholars program will provide scholarship support to selected students who are interested in working, for instance, with the Food and Drug Administration, Centers for Disease Control, National Institutes of Health, City of Hope and Children’s Hospital in Los Angeles. In addition, the program provides funding to assist students with summer internships at a government or non-profit office and for related expenses.

The Fletcher Jones Foundation has been a supporter of KGI since its founding. In 1998, the foundation awarded KGI a $1 million founding grant to support infrastructure and furnishings. Two years later, KGI received a grant of $500,000 to support the recruitment and salaries of two Fletcher Jones Assistant Professors. That grant was followed in 2003 by an award of $250,000 for continued support of the Fletcher Jones Assistant Professors.
“One hundred percent participation was very easily accomplished,” Shemeley says. “It really speaks to how cohesive our class was, and how much we understand the significance of the education we received at KGI and the importance of leaving a legacy.”

The Class of ’07 also leaves behind a quote on the alumni patio, continuing a tradition from past years. The bronze plaque reads: “Science may set limits to knowledge, but should not set limits to imagination.” –Bertrand Russell.

“We always tried to push the limits at KGI,” says Kerryann Shemeley, chair of the ‘07 class gift. “We wanted to make sure our gift was utilized,” Shemeley said of the hand-crafted, "We wanted to make sure our gift was utilized," Shemeley said of the hand-crafted, handmade bronze plaque.

Class of 2007

CLASS OF 2007

Daniel Alurovision
Ravi Amin
Jack Austin
Pradeep Bhatt
Phyllis Chan
Asia Chang
Calvin Chen
Ivy Chen
Li Chen
Jeffrey Dock
Vincent Eng
Nathan Freund
Tim Friedman
Adam Gross
Justin Hsiao
Manjiree Karandikar
Sandep Lad
Jaime Lau

NO ONE ATTENDS KGI without learning the value of applied. KGI’s curriculum was developed with the goal of teaching students that everything they learn, from business models to DNA analysis, can be applied to real world biotech problems. So it comes as no surprise that when choosing a class gift, the Class of 2007 selected as their legacy to KGI something that the school could use, or apply, over and over again, says Kerryann Shemeley, chair of the ‘07 class gift.

“KGI President Sheldon Schuster, PhD, proudly told the commencement audience that each member of the graduating class contributed towards the gift. While previous classes have had rates of 96 or 98 percent of graduates contributing, the ‘07 class could boast the rare distinction of having 100 percent involvement.

FINANCIAL HIGHLIGHTS

The First Ten Years

STATEMENTS OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th>6/30/07</th>
<th>6/30/06</th>
<th>6/30/05</th>
<th>6/30/04</th>
<th>6/30/03</th>
<th>6/30/02</th>
<th>6/30/01</th>
<th>6/30/00</th>
<th>6/30/99</th>
<th>6/30/98</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Securities Investments</td>
<td>$36,034</td>
<td>$33,147</td>
<td>$30,217</td>
<td>$28,239</td>
<td>$26,827</td>
<td>$30,156</td>
<td>$28,477</td>
<td>$24,753</td>
<td>$19,105</td>
</tr>
<tr>
<td>Private Gifts and Contracts</td>
<td>5,939</td>
<td>5,419</td>
<td>5,798</td>
<td>5,377</td>
<td>4,754</td>
<td>4,395</td>
<td>5,946</td>
<td>6,003</td>
<td>0</td>
</tr>
<tr>
<td>Total Assets</td>
<td>$44,973</td>
<td>$38,566</td>
<td>$35,915</td>
<td>$33,683</td>
<td>$31,581</td>
<td>$34,551</td>
<td>$34,423</td>
<td>$30,656</td>
<td>$25,108</td>
</tr>
<tr>
<td>LIABILITIES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonds Payable</td>
<td>$5,724</td>
<td>$7,851</td>
<td>$9,991</td>
<td>$12,132</td>
<td>$10,439</td>
<td>$10,476</td>
<td>$9,356</td>
<td>$10,984</td>
<td>$16,415</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>19,292</td>
<td>21,318</td>
<td>24,592</td>
<td>23,470</td>
<td>22,939</td>
<td>22,976</td>
<td>22,937</td>
<td>22,977</td>
<td>22,996</td>
</tr>
<tr>
<td>NET ASSETS</td>
<td>$45,681</td>
<td>$37,249</td>
<td>$31,323</td>
<td>$30,213</td>
<td>$28,642</td>
<td>$31,575</td>
<td>$31,489</td>
<td>$32,719</td>
<td>$26,614</td>
</tr>
</tbody>
</table>

STATEMENTS OF ACTIVITIES

<table>
<thead>
<tr>
<th>6/30/07</th>
<th>6/30/06</th>
<th>6/30/05</th>
<th>6/30/04</th>
<th>6/30/03</th>
<th>6/30/02</th>
<th>6/30/01</th>
<th>6/30/00</th>
<th>6/30/99</th>
<th>6/30/98</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVENUES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuition and Fees</td>
<td>$1,138</td>
<td>$601</td>
<td>$330</td>
<td>$498</td>
<td>$303</td>
<td>$41</td>
<td>$7</td>
<td>$6</td>
<td>$0</td>
</tr>
<tr>
<td>Private Gifts and Contracts</td>
<td>8,427</td>
<td>7,191</td>
<td>13,132</td>
<td>2,877</td>
<td>5,129</td>
<td>13,110</td>
<td>10,693</td>
<td>3,679</td>
<td>13,022</td>
</tr>
<tr>
<td>Investment Income</td>
<td>2,628</td>
<td>2,436</td>
<td>1,627</td>
<td>1,440</td>
<td>1,328</td>
<td>1,341</td>
<td>1,381</td>
<td>1,981</td>
<td>721</td>
</tr>
<tr>
<td>Total Revenues</td>
<td>16,817</td>
<td>14,433</td>
<td>18,563</td>
<td>7,939</td>
<td>9,515</td>
<td>15,757</td>
<td>12,968</td>
<td>4,404</td>
<td>13,763</td>
</tr>
</tbody>
</table>

FINANCIAL HIGHLIGHTS